• Low Risk of Severe COVID-19 in Children With Inflammatory Bowel Diseases

Low Risk of Severe COVID-19 in Children With Inflammatory Bowel Diseases

Pediatric patients with inflammatory bowel diseases (IBD) have a low risk of severe COVID-19, even when receiving biologic and/or other immune suppressive therapies, researchers report in Clinical Gastroenterology and Hepatology. These findings support recommendations to continue maintenance IBD treatment for pediatric patients throughout the currentpandemic. SARS-CoV2 enters human cells via

Read more
  • Summer Edition of the AGA Clinician’s Companion

Summer Edition of the AGA Clinician’s Companion

The summer edition of the AGA Clinician’s Companion—the new go-to resource for busy clinicians who can’t afford to spend hours sifting through research to find clinical value—is out! This latest edition of the AGA Clinician’s Companion, published online quarterly, summarizes research findings most relevant to clinicians on the risk of

Read more
Review: Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease

Review: Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease

Cannabis and its derivatives can have beneficial but also detrimental effects on gastrointestinal and hepatic function, via the endocannabinoid system (ECS). These are discussed in a review article in the July issue of Gastroenterology. Cannabis and its derivatives affect many gastrointestinal processes via the ECS and has reported anti-inflammatory, anti-nociceptive,

Read more

Corticosteroids, but not TNF Antagonists, Associate With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases

Increasing age, comorbidities, and use of corticosteroids and other anti-inflammatory agents correlated with severe COVID-19 in patients with inflammatory bowel diseases (IBD), whereas treatment with tumor necrosis factor (TNF) antagonists did not, researchers report in Gastroenterology. Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents (TNF antagonists such as infliximab) are commonly

Read more
  • AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA). The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but

Read more

REVIEW: Transitioning Adolescents With Inflammatory Bowel Diseases to Adult Care

Adolescents and young adults diagnosed with inflammatory bowel diseases (IBDs) in pediatric care are vulnerable during their transition to adult care. A review article in the February issue of Clinical Gastroenterology and Hepatology discusses the transition from pediatric to adult care for IBD, makes recommendations to improve this process, and identifies

Read more
  • AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

The AGA’s latest guideline provides recommendations for the management of adult outpatients with moderate to severe ulcerative colitis (UC) and adult hospitalized patients with acute severe UC. The guideline, written by Joseph D. Feuerstein et al, discusses the use of immunomodulators, biologics, and small molecules to induce and maintain remission

Read more
  • How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

Treatment of inflammatory bowel diseases (IBD) with anti-tumor necrosis factor (anti-TNF) drugs restores diversity to the intestinal microbiome, researchers report in the November issue of Gastroenterology.  The study associates metabolic interactions among luminal bacteria with outcomes of therapy. Altered interactions between the mucosal immune system and intestinal microbiota contribute to

Read more
  • Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

An individualized, food-based diet with similar composition of nutrients to exclusive enteral nutrition (EEN), causes similar changes in the microbiomes of patients with Crohn’s disease (CD), reduces gut inflammation, and is preferred by patients, researchers report in the April issue of Gastroenterology. Non-medical treatments are needed for patients with CD. Diet

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more